α:Non–α and Gγ:Aγ globin chain ratios in thalassemia intermedia patients treated with hydroxyurea

Objective: To elucidate the possible ways by which hydroxyurea molecules affect globin chain (α or β-like) synthesis. Methods: A total of 23 thalassemia intermedia patients (13 male and 10 female) aged between 5 and 26 years were treated for five months with 15 mg/(kg·day) of hydroxyurea. Hemoglobin...

Full description

Bibliographic Details
Published in:Asian Pacific Journal of Tropical Biomedicine
Main Authors: Abbas Najjari, Mohsen Asouri, Ladan Hosseini Gouhari, Haleh Akhavan Niaki, Amir Sasan Mozaffari Nejad, Seyyedeh Masoumeh Eslami, Hassan Abolghasemi, Ramin Ataee, Abdol Ali Ebrahimi, Masoumeh Rezaei Moshaei, Ali Asghar Ahmadi
Format: Article in Journal/Newspaper
Language:English
Published: Wolters Kluwer Medknow Publications 2014
Subjects:
Thalassemia intermedia
Globin chain
AUT-PAGE
Hydroxyurea
Hemoglobin
Arctic medicine. Tropical medicine
RC955-962
Biology (General)
QH301-705.5
Arctic
Sickle
Online Access:https://doi.org/10.12980/APJTB.4.2014C1161
https://doaj.org/article/3b48ae89f0834cddabaa88b28e45be4d
Description
Summary:Objective: To elucidate the possible ways by which hydroxyurea molecules affect globin chain (α or β-like) synthesis. Methods: A total of 23 thalassemia intermedia patients (13 male and 10 female) aged between 5 and 26 years were treated for five months with 15 mg/(kg·day) of hydroxyurea. Hemoglobins electrophoresis and globin chain electrophoresis was performed on each sample at different time points before and during the treatment. Results: Fetal hemoglobin increased significantly in most patients and average episodes of transfusion decreased. Both Gγ and Aγ-globin chains increased significantly and α-globin:Nonα-globin chain as well as Gγ-globin:Aγ globin chains ratios decreased. Conclusions: Improvement in α:non-α ratio and consequent decrease of free α-globin chain might be the cause of beneficial effects of hydroxyurea therapy. Two patients who felt better didn't show significant increase in their fetal hemoglobin level, and this is in contradiction with the hypothesis claiming that the HbF level increase is the cause of such therapeutic effect. In spite of the unclear mechanism of action of this drug, hydroxyurea therapy had noticeable impacts on thalassemia intermedia and also sickle cell disease and even patients suffering from thalassemia major.

Similar Items